Codexis, Inc. provides enzymatic solutions for therapeutics manufacturing, leveraging its proprietary CodeEvolver technology platform to discover, develop, and enhance novel enzymes in the United States, Canada, Latin America, Europe, the Middle East, Africa, Australia, New Zealand, Southeast Asia, and China. The company develops its proprietary ECO Synthesis manufacturing platform to enable the scaled manufacture of RNAi therapeutics through an enzymatic route. It has a license agreement with Aldevron LLC and Pfizer Inc. The company was incorporated in 2002 and is headquartered in Redwood City, California.
Enzymatic Revolution | Codexis pivots to RNAi therapeutics manufacturing, leveraging its ECO Synthesis platform to address critical challenges in drug production scalability and efficiency |
Market Opportunity | Explore the billion-dollar potential in the growing RNAi therapeutics market, where Codexis aims to revolutionize manufacturing processes with its innovative approach |
Financial Fortitude | Delve into Codexis's robust financial position, with $90.3 million in cash reserves providing runway until 2027, despite current negative EBITDA of -$45.78 million |
Analyst Outlook | Cantor Fitzgerald maintains a consistent $11.00 price target throughout 2024, reflecting cautious optimism about Codexis's potential in the RNAi manufacturing arena |
Metrics to compare | CDXS | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipCDXSPeersSector | |
---|---|---|---|---|
P/E Ratio | −3.5x | −4.7x | −0.5x | |
PEG Ratio | 1.19 | 0.08 | 0.00 | |
Price/Book | 5.2x | 1.5x | 2.6x | |
Price / LTM Sales | 5.2x | 1.7x | 3.2x | |
Upside (Analyst Target) | 125.1% | 76.1% | 41.7% | |
Fair Value Upside | Unlock | 16.7% | 6.1% | Unlock |